

REMARKS


The telephone interview with Examiner Sergeant and the undersigned on September 26, 2007 is acknowledged. The Examiner noted that claim 7 had not been amended in the last filed Amendment to recite an O-sulphated hyaluronic acid which was recited in canceled claim 1 from which canceled claim 6 depended. The absence of a signature on the last page was also noted.

The Examiner is thanked for withdrawing the final rejection in view of the Request for Continued Examination. It has been noted that claim 7 has been identified as an allowable claim provided that it was presented in independent form and included all of the limitations of the base claim from which it depended. In response, all of the rejected claims have been canceled and claim 7 has been rewritten in independent form. New claims 39-43 have been added to point out preferred aspects of the process defined by claim 7. Claim 39 points out the partial esters that may be used to make the O-sulphated hyaluronic acid derivative. Support for this claim is found in original claim 5. Claim 41-43 are supported by the specification at page 9, lines 3-10. These claims, which are dependent on claim 7, point out preferred reagents and conditions and are patentable for the same reasons that claim 7 is patentable.

This Amendment renders moot all of the rejections of record and it is believed that this application is now in condition for allowance.

An early and favorable action is earnestly solicited.

Respectfully submitted,


James V. Costigan
Registration No. 25,669

Hedman & Costigan, P.C.
1185 Avenue of the Americas
New York, NY 10036
(212) 302-8989